Clinical trial
A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
NCT02354105 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 12, 2015
- Completion date
- March 9, 2018
- Enrollment
- 680 (actual)
- Sites
- 100
Conditions
As the registry lists them; a condition with its own page is linked.